AbbVie and Allergan have waited expectantly to seal the deal on their $63 billion merger as international watchdogs took a close look at the combo. Now, they’re almost home free. The EU says it’s prepared to give a green light to the deal—and a positive view from U.S. regulators could soon follow. The European Commission approved AbbVie’s merger with Allergan on the condition the companies sell off Allergan’s late-stage IL-23 inhibitor brazikumab. That stipulation is far from a deal-breaker; Allergan already offered to offload the med, which the EU said conflicted with AbbVie’s IL-23 candidate risankizumab, along with cystic fibrosis med Zenpep. In forcing Allergan to give up brazikumab, the EU aims to avoid antitrust concerns in the irritable bowel disease market.
Read the full article: AbbVie Nears Allergan Lockup with EU Antitrust Approval //
Source: https://www.fiercepharma.com/pharma/abbvie-nears-allergan-lockup-conditional-eu-approval